一种名为 Daraxonrasib 的 KRAS 抑制剂在针对晚期胰腺癌的临床试验中展现出显著疗效,被媒体和专家誉为“数十年来最大的突破”及“最接近治愈的方法” 1234。该研究结果在巴塞罗那举行的 EORTC-NCI-AACR 分子靶点和癌症治疗研讨会上展示 2。在一项包含61名参与者的 I/II 期试验中,近90%的患者肿瘤停止生长,超过60%的患者肿瘤缩小或消失,约8%(即十二分之一)的患者在 CT 扫描中肿瘤已无法检测到 25。数据显示,接受该药物治疗一年后患者的生存率达到76.6%,远高于传统化疗通常仅为40%-45%的一年生存率 2。
尽管进展令人鼓舞,医学界强调目前尚不能将其视为彻底治愈的手段,长期疗效仍需更多时间验证 25。Dr Sam Godfrey(英国癌症研究中心)指出,这是实现“对不可成药靶点进行药物治疗”的重大飞跃;Memorial Sloan Kettering 癌症中心的 Dr Wungki Park 表示,疾病控制的持续时间几乎翻倍 5。胰腺癌在所有常见癌症中死亡率极高,在英国诊断后半年内的死亡率为50%,转移性患者五年生存率仅约3% 2;在美国,它虽占所有癌症病例的3%,却导致8%的癌症死亡人数,每年致死约53,000人 5。由于 Daraxonrasib 通过抑制驱动肿瘤生长的 RAS 突变发挥作用,未来可能惠及肺癌、卵巢癌等其他携带类似突变的癌症患者 5。
Summary
A new oral drug named Daraxonrasib has demonstrated significant efficacy in clinical trials for advanced pancreatic cancer, with results described by experts as the "biggest breakthrough in decades" and the "closest thing to a cure." 1 The medication halted tumor growth in approximately 90% of patients, while tumors vanished entirely in some cases. 2 Despite these promising outcomes, medical professionals caution that the drug is not yet a definitive cure and requires further long-term validation. 5
Clinical Trial Results
The findings were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. 2 In an early-phase trial involving 61 patients with advanced pancreatic cancer, the following results were observed:
- Tumor Response: Approximately 90% of participants experienced halted tumor growth. 2 More than 60% of patients saw their tumors shrink or disappear. 2 Notably, about 8% (or one in twelve) of patients had tumors that were undetectable on CT scans. 2
- Survival Rates: One year after treatment, 76.6% of patients remained alive. This contrasts sharply with traditional chemotherapy survival rates, which typically range between 40% and 45%. 2
- Disease Control: Dr. Wungki Park from Memorial Sloan Kettering Cancer Center noted that the duration of disease control nearly doubled compared to standard expectations. 5
Expert Commentary and Mechanism
Daraxonrasib functions as a KRAS inhibitor, targeting mutations that drive tumor growth. 2 Experts have characterized this development as "game-changing" due to its ability to treat previously "undruggable" targets. 1
Michelle Mitchell of Cancer Research UK called it "the biggest leap in decades," emphasizing the potential hope it brings to patients suffering from one of the deadliest forms of cancer. 2 Dr. Sam Godfrey, also from Cancer Research UK, highlighted that the drug represents a method for pharmacologically treating a target that was historically considered impossible to drug. 5
Context: Pancreatic Cancer Mortality
Pancreatic cancer remains the most lethal among common cancers. 2 Data indicates that the mortality rate within six months of diagnosis is 50%, and the five-year survival rate for metastatic cases is only about 3%. 2
In the United States, pancreatic cancer accounts for 3% of all cancer diagnoses but contributes to 8% of cancer deaths, resulting in approximately 53,000 fatalities annually. 5 In the United Kingdom, there are roughly 11,500 new diagnoses each year, with about 10,200 deaths. 5
Future Implications
While the results are promising, specialists emphasize that Daraxonrasib should not be viewed as a complete cure at this stage. 5 The average follow-up period in the trial was one and a half years, and long-term efficacy still needs to be verified through extended research. 5 However, because the drug targets KRAS mutations, which are also present in other cancers such as lung and ovarian cancer, researchers suggest this progress could open new therapeutic avenues for those diseases as well. 5
评论
还没有评论,欢迎留下第一条。